News & Updates
Filter by Specialty:
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
16 Sep 2022
Older age, itch, pain predict depression in atopic dermatitis
Depressive symptoms are common among adults with atopic dermatitis (AD) severity and may fluctuate over time, reveals a study. Persistent depression is significantly associated with older age, male sex, severe itch, and skin pain, among others.
Older age, itch, pain predict depression in atopic dermatitis
15 Sep 2022
Roflumilast shows treatment potential for seborrheic dermatitis
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
Roflumilast shows treatment potential for seborrheic dermatitis
15 Sep 2022
Low-dose methotrexate-related melanoma risk considered negligible
Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.
Low-dose methotrexate-related melanoma risk considered negligible
09 Sep 2022
Topical combination, physical treatments best for mild-to-moderate acne
Topical pharmacological treatment combinations, chemical peels, and photochemical therapy are deemed to be the best and the most effective options for mild-to-moderate acne vulgaris.
Topical combination, physical treatments best for mild-to-moderate acne
06 Sep 2022
No clear link between atopic dermatitis and venous thromboembolism
There appears to be no evidence that atopic dermatitis or treatment with Janus kinase (JAK) inhibitors carries an increased risk of venous thromboembolism, according to a study.